

**Table S1. Overall Response to Immunotherapies**

Patient ID.	Prior IL-2	Prior IPI	TIL	Post IPI
01	PD (CB)	na	CR	na
02	SD (CB)	na	SD	na
03	PD (CB)	na	PD	na
04	PD (CB)	na	PD	na
05	PD (CB)	na	PR	PD
06	PD (CB)	na	PD	na
07	SD (HD)	na	PR	SD
08	PD (CB)	na	SD	na
09	PR (CB)	na	PD	na
10	SD (CB)	na	SD	PD
11	PD (CB)	na	PR	na
12	PD (CB)	na	SD	na
13	nd (SC)	na	CR	na
14	SD (CB)	na	CR	na
15	PD (CB)	na	PR	na
16	PD (CB)	na	PD	na
17	na	PD	PR	na
18	PD (CB)	na	PD	na
19	CR (CB)	na	PR	PD
20	PD (CB)	na	PR	PD
21	PD (CB)	na	PR	PD
22	PD (CB)	na	SD	na
23	PD (CB)	na	SD	PD
24	SD (CB)	na	SD	PD
25	PD (CB)	na	SD	SD
26	SD (CB)	na	PR	CR
27	PD (HD)	na	SD	CR
28	PD (nd)	na	PD	na
29	SD (CB)	na	PR	PD
30	PR (CB)	na	SD	CR
31	PD (CB)	na	PR	PD
32	PD (CB)	PD	PR	na
33	PD (HD)	na	PR	PD
34	SD (CB)	na	PD	na
35	PD (IMD)	na	PD	PD
36	PR (HD)	na	CR	na
37	PD (CB)	na	PD	na
38	SD (CB)	na	PD	PD
39	PD (CB)	na	PD	PD
40	PD (CB)	na	PD	na
41	PD (CB)	na	PD	na
42	SD (CB)	PD	SD	na
43	PD (CB)	na	PD	PD
44	PD (CB)	na	PD	na
45	PD (CB)	na	PR	na
46	PD (SC)	PD	PD	na
47	PD (Inh)	na	PR	na
48	PD (HD)	SD	CR	na
49	PD (SC)	PD	PD	na
50	PD (SC)	PD	SD	na
51	CR (CB)	PD	PR	na
52	PD (CB)	PD	PD	na
53	SD (CB)	PD	PR	na
54	na	PD	PD	na
55	PD (HD)	SD	SD	na
56	PD (HD)	PD	SD	na
57	na	na	PR	na

**Supplementary Table S1: Overall Response to Immunotherapies**

The objective responses of individual patients to various types of immunotherapies, such as IL-2 based therapy (IL-2), TIL ACT (TIL) and ipilimumab (IPI) prior and post TIL ACT, are shown here. Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; CB, chemobiotherapy; HD, high-dose IL-2; SC, subcutaneous / intralesional IL-2; IMD, intermediate dose IL-2; Inh, IL-2 inhalation; na, not applicable; nd, not determined.